Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BaseTIL-02L: TIL Therapy in Advanced NSCLC
NCT06455917Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Jan 2025
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GC101 TIL + pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by University Hospital Basel. Primary endpoint: Progression-free rate at 6 months after Tumor-infiltrating lymphocytes transfer. Started Jan 2025; status: recruiting.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06455917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455917.